Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL

Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news